EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Clinical Guidance on the Safe Use of Sodium-Glucose Cotransporter Inhibitors in Adults with Type 1 Diabetes

Jayachidambaram Ambalavanan, Kanchan Bhasin, Viral N Shah

Endocrinology and Metabolism Clinics of North America · 2026-09 · 55 (3) · 537-546

DOI: 10.1016/j.ecl.2026.04.013 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2026-09. Verfasst von Jayachidambaram Ambalavanan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Maine Health Maine Medical Center and Tufts University School of Medicine, Scarborough, ME, USA. …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetic Ketoacidosis, Hypoglycemic Agents, Practice Guidelines as Topic. Die Arbeit nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium-glucose cotransporter inhibitors (SGLTi) as an adjunctive to insulin therapy may offer cardiometabolic and renal benefits in adults with type 1 diabetes (T1D). Their effective use depends on patient selection, education, and ketone monitoring to prevent diabetic ketoacidosis (DKA). Starting with the lowest effective dose, making appropriate insulin adjustments, and following structured protocols for ketone monitoring and DKA risk mitigation are essential for safe use of SGLTi in adults with T1D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Diabetic KetoacidosisHypoglycemic AgentsPractice Guidelines as TopicSodium-Glucose Transporter 2 InhibitorsSodium-Glucose Transport ProteinsHumansAdult

Stichwörter der Autor:innen

Adjunctive therapyDiabetic ketoacidosisKetone monitoringSGLTiType 1 diabetes

Substanzen

Hypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsSodium-Glucose Transport Proteins

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes and Metabolism, Maine Health Maine Medical Center and Tufts University School of Medicine, Scarborough, ME, USA. Electronic address: jay.ambalavanan@mainehealth.org.
  • Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, IN, USA.

Zitieren

APA

Ambalavanan, J., Bhasin, K., & Shah, V. N. (2026). Clinical Guidance on the Safe Use of Sodium-Glucose Cotransporter Inhibitors in Adults with Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 55(3), 537-546. https://doi.org/10.1016/j.ecl.2026.04.013

Vancouver

Ambalavanan J, Bhasin K, Shah VN. Clinical Guidance on the Safe Use of Sodium-Glucose Cotransporter Inhibitors in Adults with Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America. 2026;55(3):537-546. doi:10.1016/j.ecl.2026.04.013

BibTeX
@article{Ambalavanan2026,
  author = {Ambalavanan, Jayachidambaram and Bhasin, Kanchan and Shah, Viral N},
  title = {Clinical Guidance on the Safe Use of Sodium-Glucose Cotransporter Inhibitors in Adults with Type 1 Diabetes},
  journal = {Endocrinology and Metabolism Clinics of North America},
  year = {2026},
  volume = {55},
  number = {3},
  pages = {537--546},
  doi = {10.1016/j.ecl.2026.04.013}
}
Kostenlos starten →